Compare Omnicom Group Inc. (OMC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs ResMed Inc. — how do they compare? Omnicom Group Inc. trades at $76.35 (market cap $20.97B), while ResMed Inc. trades at $225.92 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays the higher dividend (4.19%). Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and ResMed Inc. for 51 Days on average.
| OMC | RMD | |
|---|---|---|
Market Cap | $20.97B | $31.89B |
Volume | 2,092,899 | 618,314 |
Sector | Media | Health |
52-Week High | $88.94 | $277.88 |
52-Week Low | $67.27 | $182.82 |
Typical Hold Time | 63 Days | 51 Days |
Enterprise Value | $29.05B | $31.24B |
Dividend Yield | 4.19% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $17.27B in 2025 but posted a net loss of -$54.50M due to elevated expenses. Recent news highlights leadership in digital marketing and $3.3B in new H1 2026 billings. Valuation metrics show a high P/E of 202.35 but attractive P/S of 0.84, while analyst consensus is mixed with a $104.67 price target.
OMC presents a value opportunity with its low P/S ratio and 4.2% dividend yield, offset by profitability concerns and high debt. The stock's 39% discount to consensus target suggests upside if margin improvements materialize from recent acquisitions. Key risks include advertising market volatility and integration challenges from the Interpublic deal. Institutional activity shows mixed positioning with recent trimming by major banks.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
